Edition:
United States

Nuvectra Corp (NVTR.OQ)

NVTR.OQ on NASDAQ Stock Exchange Global Market

10.20USD
23 Feb 2018
Change (% chg)

$0.15 (+1.49%)
Prev Close
$10.05
Open
$10.10
Day's High
$10.25
Day's Low
$10.05
Volume
2,829
Avg. Vol
23,064
52-wk High
$14.55
52-wk Low
$5.90

Chart for

About

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food... (more)

Overall

Beta: --
Market Cap(Mil.): $110.00
Shares Outstanding(Mil.): 10.78
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-Nuvectra Secures $45 Million Second Amendment To Existing Loan And Security Agreement

* NUVECTRA SECURES $45 MILLION SECOND AMENDMENT TO EXISTING LOAN AND SECURITY AGREEMENT

Feb 20 2018

BRIEF-Nuvectra Says Public Offering Of 2.83 Mln Shares Priced At $8 Per Share

* SAYS PUBLIC OFFERING OF 2.83 MILLION COMMON SHARES PRICED AT $8.00PER SHARE Source text for Eikon: Further company coverage:

Feb 01 2018

BRIEF-Nuvectra Sees Q4 Revenue $11.5 Mln To $12 Mln

* NUVECTRA ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2017 REVENUE

Jan 08 2018

BRIEF-Nuvectra reports Q3 loss per share $1.09

* Q3 revenue rose 102 percent to $7.6 million Source text for Eikon: Further company coverage:

Nov 01 2017

BRIEF-Nuvectra corp files for mixed shelf of upto $100 mln

* Nuvectra Corp files for mixed shelf of upto $100 million - sec filing‍​ Source text : http://bit.ly/2hQeDbP Further company coverage:

Oct 05 2017

BRIEF-Nuvectra corp says effective Aug. 31, co entered into amended and restated development agreement with Aleva Neurotherapeutics - SEC filing

* Nuvectra Corp - effective august 31, co entered into amended and restated development agreement with Aleva Neurotherapeutics, S.A - SEC filing

Sep 05 2017

Earnings vs. Estimates